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SUMMARY 
Background 
The PACE trial of treatments for chronic fatigue syndrome (CFS) found that, when added to specialist 
medical care (SMC), cognitive behaviour therapy (CBT) and graded exercise therapy (GET) were 
superior to adaptive pacing therapy (APT) and to SMC alone, in improving fatigue and physical 
functioning one year after randomisation. The aim of this paper is to report the long-term (more 
than two year) outcomes of trial participants including: (a) additional treatments received by 
patients after completing the trial; (b) changes in outcomes within the original randomised 
treatment groups; (c) differences in outcome between  these treatment groups. 
Methods 
Postal questionnaire survey measuring primary (fatigue and physical functioning) and selected 
secondary trial outcome measures sent to the 604 of the original 641 participants who had not 
withdrawn from follow-up.   
Findings 
The median time from randomisation to long-term follow-up was 31 months (range 24 to 53 
months).  We obtained usable data on 481 of 604 eligible participants (80%).  Nearly half of 
participants received treatment after the trial. The benefits of CBT and GET seen in the trial were 
maintained. Further improvements were observed in those originally allocated to CBT, SMC, and APT 
but not GET. The only difference between original treatment groups at follow up was better physical 
functioning in those allocated to CBT compared with APT (6.4, 95% CI 0.4 to 12.4, p = 0.035).  
Interpretation 
The beneficial effects of CBT and GET on fatigue and physical functioning are maintained at long-
term follow-up.  
Funding 
UK Medical Research Council, Department of Health for England, Scottish Chief Scientist Office, 
Department for Work and Pensions, National Institute for Health Research (NIHR), NIHR Biomedical 
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Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust, and King’s 
College London.  
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INTRODUCTION 
 
Chronic fatigue syndrome (CFS) is characterized by chronic disabling fatigue in the absence of an 
alternative diagnosis. Myalgic encephalomyelitis (ME) is thought by some to be the same disorder 
and by others to be different. The prevalence of CFS is between 0.2% and 2.6% worldwide 
1
. If 
untreated the prognosis for recovery is poor 
2
.  
 
We previously carried out a multi-centre randomised trial (PACE: Pacing, graded Activity and 
Cognitive behaviour therapy:  a randomised Evaluation) to compare the most commonly used non-
pharmacological treatments for CFS 
3
. When we planned the trial there was some evidence that 
cognitive behaviour therapy (CBT) and graded exercise therapy (GET) could improve patient 
outcomes.  However, these rehabilitative treatments were controversial amongst patient 
organizations and adaptive pacing therapy (APT) and specialist medical care (SMC) were regarded as 
better alternatives. The PACE trial aimed to compare the outcomes of patients who were randomly 
allocated to one of the following four treatments: SMC alone, or SMC plus APT, CBT, or GET.  The 
trial found that at the final one year (52 week) follow-up, patients who had received CBT or GET had 
significantly greater improvements in their fatigue and physical functioning than those who had 
received either APT or SMC alone. 
 
Whilst the benefits of CBT and GET seen at one year are encouraging it is clearly also important to 
know whether patients continue to experience these benefits over a longer period of time. As there 
have been few previous long-term follow-up studies of participants in trials of treatments for CFS 
4-8
 
we conducted a long-term follow-up study of the PACE trial participants.  The aims of this follow-up 
study were to: (a) describe the additional therapy (APT, CBT, GET) that participants received after 
the 12 month (52 week) final trial outcome assessment; (b) compare the outcomes of participants 
within each randomised treatment group at follow-up with the final trial outcome assessment; (c) 
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compare the long-term outcomes between the original randomised trial treatment groups, bearing 
in mind the limitations on interpretation imposed by the provision of additional, non-randomly 
allocated therapy during the follow-up period.  
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METHODS 
 
 
The PACE trial 
The PACE trial methods, including details of the trial treatments, are described in full in the main trial 
protocol and report 
9
 
3
.  In summary, this was a four-arm parallel group randomised controlled trial 
of non-pharmacological treatments for patients meeting the Oxford criteria for CFS, which require 
fatigue to be the patient’s principal symptom 
10
.  641 participants were recruited from six secondary 
care clinics in the United Kingdom and were randomly allocated to SMC alone, or SMC plus APT, CBT, 
or GET.  Participants received the therapies (APT, CBT, and GET) in one-to-one sessions (maximum 
14 sessions) during the first six months of trial participation, with an additional booster session 
offered at nine months. The trial primary outcome measures were fatigue and physical functioning, 
measured using self-report scales, at participants’ final trial outcome assessment 12 months (52 
weeks) post-randomisation.  
 
Additional therapy given after the trial 
After completing their final trial outcome assessment one year after randomisation, PACE trial 
participants were offered additional therapy if they were still unwell, they wanted more treatment, 
and their PACE trial doctor agreed this was appropriate.  The choice of type of treatment offered 
(APT, CBT, or GET) was made by the patient’s doctor taking into account both the patient’s 
preference and their own opinion of which would be most beneficial.  These choices were made 
before the overall trial findings were known.  
 
Participants in the long-term follow-up study 
We obtained consent from the 641 PACE trial participants to contact them for a long-term follow-up 
assessment at the time of trial enrolment.  19 (3%) participants withdrew consent for further data 
collection and 622 were therefore eligible to take part in the follow-up study.  
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Ethical approval 
Ethical approval for the trial and follow-up study was given by the West Midlands Multi-centre 
Research Ethics Committee (MREC 02/7/89). 
 
Procedure 
Follow-up assessments were conducted using a brief postal questionnaire.  The trial had recruited 
between March 2005 and November 2008. The follow up questionnaires were mailed to eligible 
participants from January 2008 and were timed to be at least two years after the date of their 
randomisation.   
 
Measures 
The follow-up questionnaire included the following: (a) questions about the additional therapies that 
participants had received for CFS since their final trial outcome assessment; (b) severity of fatigue 
using the Chalder Fatigue Questionnaire (CFQ) 
11
; (c) physical functioning using the SF-36 physical 
functioning subscale (SF-36PF) 
12
; (d) overall change in perceived health since trial enrolment using 
the participant-rated clinical global impression of change score (PCGI) a seven-point scale rated from 
‘very much worse’ to ‘very much better’
13
; (e) impairment of daily activities using the participant-
rated work and social adjustment scale (WSAS) scored in five domains, each rated 0 to 8, producing 
an overall score of  0 to 40, with lower scores indicating less impairment 
14
.   
 
We included the CFQ and the SF-36PF in the follow-up questionnaire because these were the 
primary outcome measures used in the PACE trial.  We chose two of the secondary trial outcome 
measures (PCGI and WSAS) in order to enhance our estimate of patient well-being whilst keeping 
the questionnaire sufficiently short to ensure a good response rate.  
Analysis 
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The variables to be analysed were first summarized using means and standard deviations, median 
and quartiles, or frequencies and proportions, as appropriate.   
We compared the proportions of eligible participants who returned follow-up questionnaires across 
the randomised treatment groups (SMC alone, SMC with APT, CBT, or GET) using Fisher’s exact test. 
We also compared the (pre-randomisation) baseline characteristics of PACE trial participants who 
did and did not take part in the follow-up study using Fisher’s exact test, independent samples t-
tests, or the Mann-Whitney U test as appropriate.  Baseline characteristics of participants in the 
subset who took part in the follow-up study were compared across original randomised treatment 
groups using Fisher’s exact test, ANOVA, or the Kruskal-Wallis test as appropriate.   
Differences between the original randomised treatment groups in the proportion of patients who 
received additional treatment after their final trial outcome assessment were compared using 
Fisher’s exact test, and in the number of additional treatment sessions by the Kruskal-Wallis test.  
We calculated differences in outcomes between the final trial assessment and long-term follow-up 
within each original treatment group using paired samples t-tests for fatigue (CFQ), physical 
functioning (SF-36PF), impairment of daily activities (WSAS), and the exact McNemar test for overall 
change in health (PCGI).  We also calculated differences in trial outcomes for those with and without 
long-term follow-up data, using independent samples t-tests.  
We constructed profile plots of fatigue (CFQ) and physical functioning (SF-36 PF) for follow-up study 
participants in each randomised treatment group, including data from baseline, 12 week, 24 weeks, 
and final one year (52 week) trial outcome assessments, and the long-term follow-up assessment.   
We assessed the differences in the measured outcomes between the original randomised treatment 
groups using linear mixed effects regression models with random intercepts and slopes for 
participants during trial participation and at long-term follow-up.  We included the following 
covariates in the models: treatment group, trial stratification variables (trial centre and whether 
participants met the International CFS criteria
15
, London ME criteria 
16
, and DSMIV depressive 
disorder criteria) 
17, 18
, time, time by treatment group interaction term, long-term follow-up data by 
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treatment group interaction term, baseline values of the outcome, and missing data predictors 
(gender, education level, Body Mass Index, and patient self-help organization membership), so the 
differences between groups obtained were adjusted for these variables.  We calculated differences 
between treatment groups on overall change in perceived health (PCGI) using a binary logistic 
generalized estimating equation model with an exchangeable working correlation and bootstrapped 
standard errors, and with similar covariates to those used in the models for the other outcomes.   
Finally we compared the proportion of participants in each treatment group who had a clinically 
useful difference (CUD) in fatigue (CFQ) and physical functioning (SF-36) scores between trial 
enrolment (baseline) and long-term follow-up.  CUD was defined in the same way as in the PACE trial 
analysis 
3
 as 0.5 of the standard deviation (SD) of the measure in the whole sample at baseline (2 
points for fatigue and 8 for physical functioning) and was compared between groups using the 
independent sample test for the difference between two proportions. 
 
Role of the funding source 
The study funder had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. MS, KG, AJ, TC and PW had full access to data collected for the study and all 
authors had final responsibility for the decision to submit the report for publication. 
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RESULTS 
 
The long-term follow-up sample 
We sent questionnaires to the 604 of the 622 patients who had consented to long-term follow-up 
for whom we had current contact details.  Of these 481/604 (80%) returned usable questionnaires 
and were included in the analysis (Figure 1).  The median (quartile) time from randomisation to long-
term follow-up assessment was 31 (30, 32) months with a range of 24 to 53 months. There were no 
differences between original randomised treatment groups in the proportions of participants who 
returned questionnaires (p=0.37).  
 [Figure 1 here] 
Table 1 shows the baseline characteristics of trial participants who did and did not take part in the 
follow-up study.  The only significant difference between these two groups was that participants 
who were members of an ME/CFS patient organization were more likely to take part in the follow-up 
study.   
[Table 1 here] 
Within the follow-up study sample there were no significant imbalances between randomised 
treatment groups in baseline characteristics (Web Appendix, Table A).  
 
Additional treatment received after the trial 
Nearly half of all the follow-up study participants received additional trial treatments after their final 
trial outcome assessment (Table 2). More detail is given in Web Appendix Table B.  The number of 
participants who received additional treatments differed between the treatment groups:  
participants allocated to SMC were most likely to receive additional treatment (63%), followed by 
those allocated to APT 60/120 (50%), then GET 41/127 (32%), and CBT 36/119 (31%).   
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In the trial analysis plan we defined an adequate number of sessions as 10 out of a maximum 
possible of 15.  Although a large number of the participants in the follow-up study had received 
additional treatment, only a minority of these had received an adequate amount as defined for the 
trial. Most of the additional treatment that was given in an adequate amount was either CBT or GET. 
[Table 2 here]  
Outcomes within randomised treatment groups at long-term follow-up  
The long-term outcomes of participants within each randomised treatment group are shown in 
Figure 2 and Table 3.  The improvements in both fatigue and physical functioning that had been 
reported by participants allocated to CBT or GET at their final trial outcome assessment were 
sustained (and had continued to improve in the CBT group). The improvements in the secondary 
measure of impairment in daily activities and in perceived health change were also sustained.  
 
Participants originally allocated to APT reported further improvements in fatigue, physical 
functioning, and impairment in daily activities from final trial outcome assessment to long-term 
follow-up, as did those allocated to SMC alone (who also reported further improvements in 
perceived health change). 
[Figure 2 here] 
[Table 3 here] 
Differences between randomised treatment groups at long-term follow-up 
The models used in the analysis adjusting for covariates and repeated measures over time indicated 
that there were no significant differences between the randomised treatment groups in mean 
fatigue scores at long-term follow-up (Web appendix, Table C).  However physical functioning was 
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still significantly better for those allocated to CBT when compared with those allocated to APT 
(p=0.035).  There were also no significant differences between originally randomised groups in 
impairment in daily activities or in perceived health change.   
Applying the criteria used in the original trial analysis plan to define a clinically useful difference 
(CUD) in both fatigue and physical functioning, improvements from baseline to long-term follow-up 
were observed  in 64/118 (54%) of those originally allocated to APT, compared with 79/119 (66%) 
for CBT, 79/127 (62%) for GET, and 65/115 (57%) for SMC; the only difference close to reaching 
significance was that between CBT and APT (p=0.056). 
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DISCUSSION 
Main findings 
The main finding of this long-term follow-up study of the PACE trial participants is that the beneficial 
effects of the rehabilitative CBT and GET therapies on fatigue and physical functioning observed at 
the final one year outcome were maintained at long-term follow-up, an average of a year and a half 
later.  
 
In interpreting the outcome data it is important to note that many of the participants in this follow-
up study had received additional treatment for CFS after the final trial outcome assessment; the 
choice of whether to give each participant additional treatments, and if so which, was made by the 
patient’s PACE trial doctor in consultation with the patient. We found that participants originally 
allocated to SMC in the trial were the most likely to receive additional treatment, followed by those 
who had APT; those originally allocated to the rehabilitative therapies (CBT and GET) were less likely 
to receive additional treatment.  In so far as the need to seek additional treatment is a marker of 
continuing illness, these findings support the superiority of CBT and GET as treatments for CFS.  
 
Participants originally allocated to SMC alone or to APT substantially improved between their final 
trial outcome assessment and the long-term follow-up.  Whilst this improvement may have been 
due to many factors including the passage of time, regression to the mean, and long-term benefits of 
the treatment received in the trial, the observation that approximately one quarter and one third of 
the participants originally allocated to APT and SMC respectively had received a therapeutically 
adequate amount (10 or more sessions) of CBT or GET after the trial final trial outcome, makes it 
likely that this additional treatment was important in improving the long-term outcome for these 
patients. 
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There was little evidence of deterioration (negative change) in the participant rated clinical global 
impression change scale (PCGI) in the whole sample at long term follow-up and importantly there 
were no significant differences in deterioration rates between the originally allocated treatment 
groups. This finding suggests that none of the trial therapies are associated with long-term 
deterioration. 
 
When outcomes were compared between the originally randomised groups, few differences were 
seen. This convergence in outcomes reflects the observed improvement in those originally allocated 
to SMC and APT, the possible reasons for which are listed above.  
 
Previous studies 
There have been a number of previously published naturalistic follow-up studies of the outcome of 
patients with CFS.  A systematic review found 14 studies of subjects meeting operational criteria for 
CFS with a variety of follow-up durations and outcome measures and concluded that the prognosis 
was generally poor; improvement was reported by a median of 40% of participants and recovery by 
only 7% 
2
.  There have also been several small follow-up studies of patients who have received 
specific treatment, almost all CBT: a four-year follow-up of a small case series found that most of the 
patients had maintained their improvement 
19
. A five -year follow-up of a small randomised trial of 
adults receiving CBT found persisting improvement 
4
. Similar sustained improvements were found 
after CBT in a two-year follow-up of adolescents 
5
,  a two year follow-up of family focused CBT in 
adolescents 
7
, and a 2.7 year follow-up of adolescents treated in a trial comparing internet delivered 
CBT with usual care 
8
. There has however been no follow-up study of GET, although a two-year 
follow-up of a randomised trial of an educational intervention which included advice on graded 
activity found the benefits were maintained 
6
. There are also no published follow-up studies of 
treatment with APT.  
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Our findings confirm reports indicating that improvements from  
CBT are maintained in the long-term. A new finding is that long-term benefit also occurs following 
GET.  
 
Limitations 
This follow-up study has a number of limitations. First, the response rate was incomplete; there may 
have been some selection bias in those who returned follow-up questionnaires that led to an 
underestimate of the actual differences between the groups. Second, there was variation in the 
duration of follow-up.  Third, the outcomes were self-rated and therefore potentially subject to bias. 
Finally, the supplementation of the originally randomly allocated treatment with additional 
treatment after the trial final outcome limits the conclusions that can be drawn from the between 
group comparisons.  
 
Conclusion 
We can conclude that the benefits of CBT and GET for patients with CFS are maintained at long-term 
(two and a half year) follow-up. We can also confirm that there was no evidence of deterioration in 
overall health from the trial final outcome assessment to follow up after any trial treatment. We 
note however that in all of the originally randomised treatment groups some patients remain unwell 
at long-term follow-up, an observation that reminds us that better treatments are still needed for 
those patients. 
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PANEL: RESEARCH IN CONTEXT 
Evidence before this study 
For the original adaptive Pacing, graded Activity and Cognitive behaviour therapy; a randomised 
Evaluation (PACE) trial report, PubMed and Cochrane Library databases were searched to Nov 6th, 
2010. The findings of this systematic review are shown in the ‘Research in Context’ panel of that 
publication. The review concluded that the untreated outcome for patients with chronic fatigue 
syndrome (CFS) was poor, and that there was some evidence that cognitive behaviour therapy (CBT) 
and graded exercise therapy (GET) improved this 
3.
 The PACE trial confirmed that CBT and GET were 
more effective than specialist medical care alone (SMC) in improving fatigue and functioning one 
year after randomisation but that adaptive pacing (APT) was not
 3.
  For this study we searched 
PubMed to February 1st, 2015 for follow up studies of more than one year of patients who had 
received a PACE trial treatment.  The reports identified were small studies and almost all of patients 
who had received CBT. They suggested that the benefits from CBT are maintained 
19
 
4
 
5
 
8
. We did not 
find any long-term follow-up study after GET (although a single follow up of an educational 
intervention which included advice on graded activity found the benefits were maintained 
6
) or APT. 
 
Added value of this study 
Our long-term follow up of the PACE trail participants adds to what we already knew by providing 
robust evidence that the improvements in fatigue and function observed with CBT and GET are 
maintained in the longer-term (a mean of two and a half years from randomisation).  It does not 
provide evidence that CBT and GET are better than SMC and APT in the longer term, as patients 
allocated to these treatment had improved to a similar degree by the time of the follow up, but the 
interpretation of this finding is complicated by the fact that many of these patients had received CBT 
or GET between the end of the trial and the long–term follow up. Importantly there was no 
significant worsening in perceived health during the follow up period after any of the trial 
treatments. 
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Implications of all the available evidence 
Taken together the available evidence confirms that the rehabilitative treatments of CBT and GET for 
CFS are associated with long term improvement in fatigue and functioning for patients with CFS. 
However, the observation that some patients remain unwell at long-term follow-up reminds us that 
more effective treatments are still needed for these patients. 
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FIGURES AND TABLES 
Figure 1.  Participation in the long-term follow-up study 
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Figure 2. Unadjusted mean profile plots of fatigue and physical functioning by randomised 
treatment group for participants in the long-term follow-up study 
 
 
 
Data are unadjusted means and 95% confidence intervals for the main trial time points (0, 12, 24, 
and 52 weeks post-randomisation) and long-term follow-up (*median 134 weeks). 
w = weeks, APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise 
therapy, SMC = specialist medical care 
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Table 1. Baseline characteristics of PACE trial participants who did and did not take part in the 
follow-up study 
 
 
Participated 
n=481 
 
 
Did not 
participate 
n=159* 
 
 
p-value**  
Age (years)    38.6 (12.0) 37.5 (11.4) 0.33 
Female sex 366 (76) 129 (81) 0.23 
White ethnicity 451 (94) 144 (92) 0.45 
CFS/ME patient group membership   0.015 
  Local self-help group for CFS/ME only  30 (6)   3 (2)  
  National CFS/ME patient organization only  46 (10)   8 (5)  
  Both  11 (2)   7 (4)  
  None 394 (82) 141 (89)  
International  criteria for CFS met 319 (66) 108 (68) 0.71 
London criteria for ME met 252 (52)  77 (48) 0.41 
Depressive disorder  152 (32)  61 (38) 0.12 
Any psychiatric disorder 220 (46) 80 (50) 0.36 
Duration of CFS (months)  32 (16, 66) 30 (18, 76) 0.90 
Body Mass Index 25.3 (4.8) 25.9 (5.4) 0.20 
  
Data are mean (SD), n (%) or median (25
th
 percentile, 75
th
 percentile). 
CFS = chronic fatigue syndrome, ME = myalgic encephalomyelitis 
 
* One trial participant withdrew consent for any use of their data after completion of the trial and 
did not return a long-term follow-up questionnaire. 
**Fisher’s exact test (categorical variables), independent samples t-test (continuous variables) or 
Mann-Whitney U test (illness duration) p-value for difference across treatment groups. 
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Table 2.  Additional treatment received after final 12 month (52 week) trial outcome assessment 
 
 
All follow-
up study 
participants 
n = 481 
SMC 
n = 115 
APT 
n = 120 
CBT 
n = 119 
GET 
n = 127 
p-value** 
Number (%) of 
participants who 
received any 
additional sessions* 
210 (44) 73 (63) 60 (50) 36 (31) 41 (32) <0.001 
Median (quartiles) 
number of 
additional sessions 
received 
0 (0, 8) 6 (0, 12) 1 (0, 8) 0 (0, 3) 0 (0, 6) <0.001 
Number (%) of participants who received an adequate number (10 or more) sessions of therapy 
received APT 15 (3) 6 (5) 0 2 (2) 7 (6) 0.016 
received CBT 65 (14) 23 (20) 20 (17) 2 (2) 20 (16) < 0.001 
received GET 26 (5) 14 (12) 7 (6) 5 (4) 0 < 0.001 
 
Data are n (%) or median (25
th
 percentile, 75
th
 percentile).  
APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, 
SMC = specialist medical care alone 
 
*Two participants indicated that they had additional sessions of a single type of therapy but the 
number of sessions received was missing; one was in the CBT group and had additional GET and the 
other was in the APT group and had additional APT. 
**Fisher’s exact test p-value for difference between treatment groups, except for number of 
additional sessions of therapy which is a Kruskal-Wallis test p-value. 
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Table 3. Summary statistics and within-group comparisons of long-term follow-up and final trial 
outcome assessment of PACE trial participants  
 
 SMC                          APT CBT GET                        
Fatigue (CFQ) 
Baseline n 160 159 161 160 
Mean (SD) 28.3 (3.6) 28.5 (4.0) 27.7 (3.7) 28.2 (3.8) 
52 weeks n 152 153 148 154 
Mean (SD) 23.8 (6.6) 23.1 (7.3) 20.3 (8.0) 20.6 (7.5 
Long-term n 115 120 119 127 
Mean (SD) 20.2 (8.6) 20.5 (8.4) 18.4 (8.5) 19.1 (7.9) 
Comparison n 114 119 118 127 
Mean difference (CI) -3.9 (-5.3, -2.6) 
p < 0.001 
-3.0 (-4.4, -1.6) 
p < 0.001 
-2.2 (-3.7, -0.6) 
p = 0.006 
-1.3 (-2.7, 0.1) 
p = 0.059 
Physical functioning (SF-
36PF) 
Baseline n 160 159 161 160 
Mean (SD) 39.2 (15.4) 37.2 (16.9) 39.0 (15.3) 36.7 (15.4) 
52 weeks  n 152 153 148 154 
Mean (SD) 50.8 (24.7) 45.9 (24.9) 58.2 (24.1) 57.7 (26.5) 
Long-term* n 115 118 119 127 
Mean (SD) 57.4 (27.9) 52.8 (30.2) 62.2 (27.2) 59.8 (27.6) 
Comparison n 114 117 118 127 
Mean difference (CI) 7.1 (4.0, 10.3) 
p < 0.001 
8.5 (4.5, 12.5) 
p < 0.001 
3.3 (0.02, 6.7) 
p = 0.049 
0.5 (-2.7, 3.6) 
p = 0.78 
Overall change in 
perceived health (PGCI) 
52 weeks  n 152 153  147 152 
positive change n (%)  38 (25)  47 (31)  61 (42)  62 (41) 
no change 100 (66)  96 (63)  77 (52)  80 (53) 
negative change  14 (9)  10 (7)   9 (6)  10 (7) 
Long-term n 115 118 119 127 
positive change n (%)  48 (42)  45 (38)  50 (42)  61 (48) 
no change  58 (50)  59 (50)  57 (48)  59 (47) 
negative change   9 (8)  14 (12)  12 (10)   7 (6) 
Comparison n 
Difference in positive 
change percentage (CI) 
114 
18 (7, 28) 
p = 0.001 
117 
9 (-1, 18) 
p = 0.099 
117 
-3 (-11, 6) 
p = 0.68 
125 
2 (-7, 12) 
p = 0.71 
Difference in negative 
change percentage  (CI) 
-4 (-11, 4) 
p = 0.42 
6 (-1, 13) 
p = 0.12 
6 (-0.8, 13) 
p = 0.092 
-2 (-7, 4) 
p = 0.73 
Impairment of daily 
activities  (WSAS) 
Baseline n 160 158 161 160 
Mean (SD) 26.9 (6.7) 27.9 (6.1) 27.4 (6.2) 26.8 (6.1) 
52 weeks  n 151 150 143 144 
Mean (SD) 23.9 (9.2) 24.5 (8.8) 21.0 (9.6) 20.5 (9.4) 
Long-term n 115 120 119 126 
Mean (SD) 21.1 (11.5) 22.9 (11.7) 19.7 (10.2) 19.4 (10.8) 
Comparison n 
Mean difference (CI) 
113 
-3.2 (-4.7, -1.6) 
p < 0.001 
118 
-2.2 (-3.8, -0.6) 
p = 0.007 
117 
-0.9 (-2.2,  0.4) 
p = 0.18 
120 
 -1.0 (-2.5,  0.4) 
p = 0.16 
 
All differences are between long term follow-up and 52 weeks. Mean differences and 95% 
confidence intervals for fatigue, physical functioning and work and social adjustment scale, 
difference in proportions with positive and negative change and 95% confidence intervals for overall 
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change in perceived health as compared to baseline.  Lower scores are better for fatigue and work 
and social adjustment, higher scores are better for physical functioning.  P-values for fatigue, 
physical functioning and work and social adjustment scale from paired samples t-tests; p-values for 
patient rated clinical global impression from McNemar test. 
 
APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, 
SMC = specialist medical care alone, CFQ = Chalder Fatigue Questionnaire, SD = standard deviation, 
SF-36PF = SF-36 physical functioning subscale, WSAS =Work and Social Adjustment Scale, PGCI 
=participant-rated clinical global impression of change score.  CI = confidence interval  
 
*Two participants left the entire SF36 PF questionnaire blank at long-term follow-up and so were 
missing the physical functioning outcome measure.   
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WEB APPENDIX 
 
Table A.  Baseline characteristics of follow-up study participants by randomised treatment group  
 
 SMC 
n=115 
APT 
n=120 
CBT 
n=119 
GET 
n=127 
p-value* 
Age (years) 37.3 
(11.3) 
38.3 
(11.5) 
39.8 
(12.1) 
38.8 
(13.1) 
0.47 
Female sex 82 (71) 94 (78) 95 (80) 95 (75) 0.43 
White ethnicity 109 (96) 111 (93) 112 (94) 119 (94) 0.89 
CFS/ME patient group membership      0.59 
  None 98 (85) 94 (78) 97 (82) 105 (83)  
  Local self-help group for CFS/ME 
only  
4 (4) 9 (8) 7 (6) 10 (8)  
  National CFS/ME patient  
  organization only 
10 (9) 15 (13) 13 (11) 8 (6)  
  Both 3 (3) 2 (2) 2 (2) 4 (3)  
International criteria for CFS  
75 (65) 
83 (69) 76 (64) 85 (67) 
 
0.84 
London criteria for ME  
61 (53) 
60 (50) 62 (52) 69 (54) 
 
0.92 
Current depressive disorder   
36 (31) 
40 (33) 37 (31) 39 (31) 
 
0.97 
Any psychiatric comorbidity  
 
 
52 (45) 
58 (48) 55 (46) 55 (43) 0.89 
Duration of CFS (months) 
29 (15, 58) 
32 (16, 
67) 
33 (15, 
105) 
33 (16,  
63) 
0.44 
 
BMI  
 
25.1 (4.6) 25.2 (5.2) 25.3 (5.1) 25.6 (4.3) 0.84 
 
 
Data are n (%), mean (SD), median (25
th
 percentile, 75
th
 percentile). 
SMC = Standard medical care alone, APT = adaptive pacing therapy, CBT = cognitive behaviour 
therapy, GET = graded exercise therapy, CFS = chronic fatigue syndrome, ME = myalgic 
encephalomyelitis, BMI = body mass index 
 
*Fisher’s exact test (categorical variables), ANOVA (continuous variables), or Kruskal-Wallis test 
(illness duration) p-value for difference across treatment groups. 
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Table B. Number of additional therapy received after final 12 month (52 week) trial outcome 
assessment 
 
 Original randomised treatment group 
Additional sessions SMC 
n=115 
APT 
n=120 
CBT 
n=119 
GET 
n=127 
Overall 
n = 481* 
SMC sessions      
None   94 (82) 101 (84) 101 (85) 111 (87) 407 (85) 
1 to 4   12 (10)  17 (14)  14 (12)  15 (12)  58 (12) 
5 to 9    7 (6)   1 (1)   4 (3)   1 (1)  13 (3) 
10 or more    2 (2)   1 (1)   0   0   3 (1) 
APT sessions      
None  102 (89) 114 (96) 111 (93) 116 (91) 443 (92) 
1 to 4    0   3 (3)   4 (3)   0   7 (2) 
5 to 9    7 (6)   2 (2)   2 (2)   4 (3)  15 (3) 
10 or more    6 (5)   0   2 (2)   7 (6)  15 (3) 
CBT sessions      
None  75 (65)  81 (68) 109 (92)  98 (77) 363 (76) 
1 to 4    3 (3)  11 (9)   4 (3)   3 (2)  21 (4) 
5 to 9   14 (12)   8 (7)   4 (3)   6 (5)  32 (7) 
10 or more   23 (20)  20 (17)   2 (2)  20 (16)  65 (14) 
GET sessions      
None   84 (73)  97 (81)  95 (81) 123 (97) 399 (83) 
1 to 4    8 (7)   7 (6)   6 (5)   2 (2)  23 (5) 
5 to 9    9 (8)   9 (8)  12 (10)   2 (2)  32 (7) 
10 or more   14 (12)   7 (6)   5 (4)   0  26 (5) 
 
Data are n (%).  
SMC = specialist medical care alone, APT = adaptive pacing therapy, CBT = cognitive behaviour 
therapy, GET = graded exercise therapy,  
 
*Two participants indicated that they had additional sessions of a single type of therapy but data on 
the number of sessions were missing; one was in the CBT group and had additional GET and the 
other was in the APT group and had additional APT. 
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Table C. Differences in outcomes between originally randomised treatment groups* 
 
                         APT 
                        
CBT 
                          
GET                       
Fatigue (CFQ) 
Compared with SMC 
P 
0.3 (-1.7, 2.3) 
0.78 
-1.4 (-3.4, 0.7) 
0.19 
-0.8 (-2.8, 1.2) 
0.43 
Compared with APT 
P -- 
-1.6 (-3.6, 0.3) 
0.11 
-1.1 (-3.0, 0.9) 
0.28 
Physical function (SF-36PF) 
Compared with SMC 
P 
-3.6 (-9.6, 2.4) 
0.24 
2.8 (-3.2, 8.8) 
0.36 
2.0 (-4.0, 7.9) 
0.51 
Compared with APT 
P -- 
6.4 (0.4, 12.4) 
0.035 
5.6 (-0.3, 11.5) 
0.064 
    
    
Overall change in perceived health 
(PGCI)  
Compared with SMC 
P 
0.8 (0.4, 1.3) 
0.32 
0.9 (0.5, 1.5) 
0.62 
1.1 (0.6, 1.8) 
0.85 
Compared with APT 
P 
 
-- 
1.2 (0.7, 2.0) 
0.59 
1.4 (0.8, 2.3) 
0.22 
Impairment of daily activities (WSAS) 
Compared with SMC 
P 
1.3 (-1.2, 3.7) 
0.30 
-1.1 (-3.6, 1.4) 
0.38 
-0.8 (-3.2, 1.6) 
0.51 
Compared with APT 
P  
-2.4 (-4.8, 0.1) 
0.06 
-2.1 (-4.5, 0.3) 
0.09 
 --   
 
Mean differences between specified groups and 95% confidence intervals for fatigue, physical 
function, and work and social adjustment obtained from linear mixed effects models.  Odds ratios 
for comparisons to specified group and 95% confidence intervals for overall change in perceived 
health obtained from generalized estimating equation models comparing positive change to 
no/negative change.  Differences of negative magnitude for fatigue and work and social adjustment 
are favoured as the direction of these scales is lower is better, differences of positive magnitude for 
physical function are favoured as the direction of this scale is higher is better.  For overall change in 
perceived health, odds ratios of greater than 1 are favoured, as the proportion with positive change 
is being compared. 
APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, 
CFQ = Chalder Fatigue Questionnaire, SMC = specialist medical care, SF-36PF = SF-36 physical 
function subscale, PGCI =participant-rated clinical global impression of change score, WSAS =Work 
and Social Adjustment Scale.   
*There is no column for SMC as this was only used as a comparison group 
 
 
 
